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Abstract
Objectives: Considering the dearth of literature on West syndrome (WS) from South 
Asian countries, this study aimed to evaluate the management practices in South Asia 
by an online survey and meta-analysis.
Methods: An online questionnaire was sent to 223 pediatric neurologists/pediatri-
cians in India, Pakistan, Myanmar, Sri Lanka, Bhutan, Nepal, and Bangladesh. Their 
responses were evaluated and supplemented by a meta-analysis.
Results: Of 125 responses received (response rate: 56%), around 60% of responders 
observed male preponderance and an approximate lead-time-to-treatment (LTTT) of 
4-12 weeks. The commonest etiology observed was a static structural insult (88.6% 
of responders). Most commonly used first-line drug (country-wise) was as follows: 
India—adrenocorticotropin hormone (ACTH, 50%); Pakistan—oral steroids (45.5%); 
Myanmar, Sri Lanka, and Nepal—oral steroids (94.4%); Bangladesh—ACTH (2/2); 
Bhutan—vigabatrin (3/5). ACTH and vigabatrin are not available in Myanmar and 
Nepal. The most commonly used regime for ACTH was maximal-dose-at-initia-
tion-regime in India, Sri Lanka, and Bangladesh and gradually escalating-regime 
in Pakistan. Maximum dose of prednisolone was variable—most common response 
from India: 3-4 mg/kg/d; Pakistan, Bhutan, and Bangladesh: 2 mg/kg/d; Sri Lanka, 
Nepal, and Myanmar: 5-8 mg/kg/d or 60 mg/d. The total duration of hormonal ther-
apy (including tapering) ranged from 4 to 12 weeks (67/91). Most responders consid-
ered cessation of spasms for four weeks as complete response (54/111) and advised 
electroencephalography (EEG; 104/123) to check for hypsarrhythmia resolution. 
Difficult access to pediatric EEG in Bhutan and Nepal is concerning. More than 
95% of responders felt a need for more awareness. The meta-analysis supported the 
preponderance of male gender (68%; confidence interval [CI]: 64%-73%), structural 
etiology(80%; CI 73%-86%), longer LTTT (2.4 months; CI 2.1-2.6 months), and low 
response rate to hormonal therapy(18% and 28% for ACTH and oral steroids respec-
tively) in WS in South Asia.
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1 |  INTRODUCTION
West syndrome (WS), the commonest epileptic encepha-
lopathy in infancy, is characterized by clustered epilep-
tic spasms and a pathognomonic electroencephalographic 
(EEG) pattern of hypsarrhythmia.1 Infantile spasms (IS) 
and WS are often used synonymously but IS also encom-
passes epileptic spasms with or without a cluster, and EEG 
abnormalities (even without hypsarrhythmia). WS/IS com-
prises 2% of childhood epilepsies and 13%-45% of infan-
tile-onset epilepsies.2–4 These may be caused by an array 
of etiologies, including structural, metabolic, and genetic 
variations.
Diagnosis of WS warrants early and aggressive treatment 
because early control of epileptic spasms and shorter lead-
time-to-treatment (LTTT) have been associated with better 
outcomes, especially in cases with unknown etiology.5 The 
therapeutic options include vitamin trials (pyridoxine, pyri-
doxal phosphate, and folinic acid in cryptogenic WS), hor-
monal therapy [intramuscular adrenocorticotrophic hormone 
(ACTH)/ oral steroids], and vigabatrin. ACTH (level B) or vi-
gabatrin (level C) may be advised as the first-line treatment of 
WS and ACTH has an edge on vigabatrin (level C).2,6 Besides 
these first-line options, there is growing literature available 
on other drugs such as zonisamide and topiramate.7,8
A recent meta-analysis estimated the pooled incidence of 
WS/IS to be 0.249 cases/1000 live births with a pooled preva-
lence of 0.015 cases/1000 population and a higher prevalence 
in Scandinavian countries.9
However, the included studies were predominantly from 
North America, Europe, and parts of Asia (Japan, Taiwan, 
South Korea, Kazakhstan, China, Singapore, and India). The 
underrepresentation of African and Asian continent in this 
review strongly implies a dearth of literature on WS/IS from 
these countries. Also, there are several other crucial facets 
that need to be addressed in the management of WS. These 
include frequent misdiagnosis, diagnostic and treatment lag, 
availability of and familiarity with treatment modalities, 
quantification of response to treatment, and neurodevelop-
mental sequelae.10,11 These fronts are handled differently 
in not only different clinical setups but also in different 
nations.12–14
There are several known disparities in the practices for 
the management of WS in Asia as compared with Europe 
and North America. These include poor access to pediatric 
neurology services, preponderance of structural etiology, 
nonavailability of ACTH and vigabatrin in some countries, 
cost of vigabatrin, increased risk of tropical infections, and 
constraint of resources.13,14 Also, many of the South Asian 
countries lack published literature on their practices, expe-
rience, and problems. Hence, the ground reality of some of 
these countries is not known. Therefore, the current study 
aimed to capture the prevailing practices for the management 
of WS in South Asia by means of an online survey. The sec-
ondary objective was to carry out a meta-analysis of the ex-
isting literature covering this aspect.
2 |  METHODS
The descriptive, cross-sectional survey study was designed at a 
tertiary care hospital in northern India. This study was conducted 
over seven months (March to September 2019) after approval 
from the Institutional Ethics Committee (IEC/2018/002183). 
A questionnaire consisting of 36 questions was prepared. The 
questions pertained to (a) responders' demographics and quali-
fication, (b) epidemiological variables (gender preponderance, 
etiology of WS), (c) diagnosis of WS (diagnostic modalities 
Significance: This study highlights the practices and challenges in the management 
of WS in South Asia. These include a preponderance of male gender and structural 
etiology, a longer LTTT, difficult access to pediatric EEG, nonavailability of ACTH 
and vigabatrin in some countries, and low effectiveness of hormonal therapy in this 
region.
K E Y W O R D S
Asia, epileptic spasms, hypsarrhythmia, infantile spasms, low middle-income countries
Key Points
• There is preponderance of male gender and struc-
tural etiology in South Asian children with West 
syndrome.
• The response rates to hormonal therapy in WS are 
low in South Asia
• Difficult access to pediatric EEG and nonavaila-
bility of ACTH and vigabatrin are the other prob-
lems in some of this region.
• There is a growing fondness for oral steroids in 
WS in South Asia.
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used, treatment lag, and its causes), (d) treatment (preferred 
order of treatment, availability and licensing of first-line drugs, 
treatment regimen followed for hormonal therapy, and vigaba-
trin), (e) response assessment (clinical and electroencephalo-
graphic) in responder's clinical setting. Although the response 
to a few questions was compulsory, responding to each ques-
tion was not mandatory to proceed to the next question. This 
was done to get a better response rate.
An online survey was designed using Google forms. The 
link to the survey was shared via emails with a total of 223 
pediatric neurologists/pediatricians in India (165), Pakistan 
(22), Myanmar (11), Bhutan (10), Sri Lanka (8), Nepal (5), 
and Bangladesh (2). In India, the mailing list of the pediatric 
neurologists and pediatricians with a special interest in neu-
rology who are part of the Association of Child Neurology 
(AOCN), India, was primarily used for the survey. A coinves-
tigator was identified at Pakistan, Nepal, Bhutan, Sri Lanka, 
and Myanmar who shared the survey link with the practi-
tioners managing WS in their respective country. However, a 
coinvestigator could not be identified in Bangladesh, and the 
F I G U R E  1  Country-wise survey response rate and preferred first-choice drug for West syndrome in South Asia. Bar diagram showing the 
response rate to the survey across the seven South Asian countries (A) and responses for the first-choice drug used in West syndrome (B)
464 |   MADAAN et Al.
T
A
B
L
E
 1
 
R
es
po
ns
es
 o
f p
ed
ia
tri
ci
an
s/
 p
ed
ia
tri
c 
ne
ur
ol
og
is
ts
 m
an
ag
in
g 
W
es
t s
yn
dr
om
e 
to
 th
e 
su
rv
ey
 q
ue
st
io
ns
Q
ue
st
io
n 
(n
um
be
r 
of
 r
es
po
ns
es
 r
ec
ei
ve
d)
In
di
a
Pa
ki
st
an
M
ya
nm
ar
Sr
i L
an
ka
Bh
ut
an
N
ep
al
Ba
ng
la
de
sh
To
ta
l n
 (%
)
N
um
be
r o
f r
es
po
ns
es
 fo
r e
ac
h 
co
un
try
76
22
9
6
5
3
2
12
3
Q
ua
lif
ic
at
io
n 
of
 re
sp
on
de
rs
 (1
23
)
M
D
/ D
N
B
 P
ed
ia
tri
cs
 w
ith
 e
xp
er
ie
nc
e
23
4
2
0
5
1
1
40
 (3
2.
5%
)
Q
ua
lif
ie
d 
in
 n
eu
ro
lo
gy
/ e
pi
le
ps
y
53
18
7
6
—
2
1
83
 (6
7.
5%
)
M
al
e 
pr
ep
on
de
ra
nc
e 
ob
se
rv
ed
 (1
23
)
45
14
4
4
3
2
2
74
 (6
0.
2%
)
A
pp
ro
xi
m
at
e 
le
ad
 ti
m
e 
to
 tr
ea
tm
en
t (
12
3)
<
4 
w
11
2
—
4
1
1
—
19
 (1
5.
4%
)
4 
w
 to
 3
 m
o
45
10
8
2
3
2
1
71
 (5
7.
7%
)
3 
m
o 
to
 6
 m
o
18
6
1
—
1
—
1
27
 (2
2%
)
>
6 
m
o
2
4
—
—
—
—
—
6 
(4
.9
%
)
C
om
m
on
 c
au
se
s o
f t
re
at
m
en
t l
ag
 (1
23
; m
ul
tip
le
)
La
ck
 o
f r
ec
og
ni
tio
n 
as
 se
iz
ur
e 
by
 p
ar
en
ts
72
15
9
6
4
3
2
11
1(
90
.2
%
)
Po
or
 a
cc
es
si
bi
lit
y 
to
 m
ed
ic
al
 fa
ci
lit
y
23
8
4
1
1
1
2
40
 (3
2.
5%
)
M
is
di
ag
no
si
s b
y 
at
te
nd
in
g 
ph
ys
ic
ia
n
57
13
5
3
3
3
1
85
 (6
9.
1%
)
La
ck
 o
f E
EG
 fa
ci
lit
y
10
2
0
0
5
2
1
20
 (1
6.
3%
)
Ti
m
e 
ta
ke
n 
fo
r i
nv
es
tig
at
io
ns
 E
EG
/M
R
I
15
8
0
0
3
2
2
30
 (2
4.
4%
)
 P
ro
vi
si
on
 fo
r f
re
e 
di
ag
no
si
s a
nd
 tr
ea
tm
en
t 
of
 c
hi
ld
re
n 
w
ith
 W
es
t s
yn
dr
om
e(
12
3)
32
9
7
6
5
1
0
60
 (4
8.
8%
)
W
ha
t i
s t
he
 m
os
t c
om
m
on
 c
au
se
 o
f W
es
t s
yn
dr
om
e 
in
 y
ou
r p
ra
ct
ic
e?
 (1
22
)
St
at
ic
 in
su
lt 
se
qu
el
ae
: H
yp
ox
ic
-is
ch
em
ic
/ 
H
yp
og
ly
ce
m
ic
 b
ra
in
 in
ju
ry
 e
tc
73
14
9
6
(R
es
po
ns
e:
 
4/
5)
 2
3
1
10
8 
(8
8.
6%
)
Tu
be
ro
us
 S
cl
er
os
is
 C
om
pl
ex
—
—
—
—
2
—
—
2 
(1
.6
%
)
In
bo
rn
 e
rr
or
s o
f m
et
ab
ol
is
m
1
1
—
—
—
—
—
2 
(1
.6
%
)
G
en
et
ic
 c
au
se
s
2
7
—
—
—
—
1
10
 (8
.2
%
)
Fi
rs
t c
ho
ic
e 
of
 d
ru
g 
us
ed
 (1
23
)
A
C
TH
 IM
38
1
—
—
—
—
2
41
 (3
3.
4%
)
A
C
TH
 +
 V
ig
ab
at
rin
5
—
—
—
—
—
—
5 
(4
.1
%
)
O
ra
l s
te
ro
id
s
27
10
9
6
2
2
—
56
 (4
5.
5%
)
O
ra
l v
al
pr
oa
te
5
4
—
—
—
1
—
10
 (8
.1
%
)
O
ra
l v
ig
ab
at
rin
—
7
—
—
3
—
—
10
 (8
.1
%
)
St
er
oi
d 
+
 v
ig
ab
at
rin
1
—
—
—
—
—
—
1 
(0
.8
%
) (C
on
tin
ue
s)
   | 465MADAAN et Al.
survey link was shared with only two pediatric neurologists 
with already known contact details. The nonresponders were 
encouraged by frequent emails. The responses were analyzed 
by using Statistical Package for Social Sciences, version 22 
software (IBM Corporation, Armonk, NY, USA).
The existing literature from South Asia was systemati-
cally reviewed and a meta-analysis for several variables (gen-
der, etiology, lead time to diagnosis/treatment (LTTD/LTTT), 
and response rate to ACTH and oral steroids, respectively) 
was done to authenticate the results of the survey. Preferred 
reporting items for systematic reviews and meta-analyses 
(PRISMA) diagram and detailed methodology are illustrated 
in Figure S1 and Table S1.
3 |  RESULTS
3.1 | Results of the survey
One hundred twenty-five responses were received [response 
rate: 56%; India (76/165), Pakistan (22/22), Myanmar (9/11), 
Sri Lanka (6/8), Bhutan (5/10), Nepal (3/5), Bangladesh 
(2/2), and outliers (2/165; UK and UAE); Figure 1A]. Most 
responders from India (53/76), Pakistan (18/22), Myanmar 
(7/9), Sri Lanka (6/6), and Nepal (2/3) were qualified pediat-
ric neurologists/epileptologists. The key responses are dem-
onstrated in Table 1.
Around 60% of responders (74/123) observed gender 
preponderance for males in their experience. Treatment lag 
was fairly common in the South Asian subcontinent. Most 
responders (71/123; 58%) suggested that approximate LTTT 
in their respective countries ranged from 4 to 12  weeks. 
However, some regional differences were noted, such as most 
responders from Sri Lanka (4/6) observing a shorter LTTT 
of fewer than four weeks. Most responders felt that the com-
monest cause of treatment lag was lack of event recognition 
as a seizure by parents (111/123; 90%) followed by misdiag-
nosis by attending physician (85/123; 69%). Besides these, 
a lack of pediatric EEG facilities in Bhutan (5/5) and Nepal 
(2/3) is a matter of concern. Most responders from Bhutan, 
Sri Lanka, and Myanmar had provision for free diagnosis and 
management of children with WS while this was applicable 
for around 40% responders from India, Pakistan, and Nepal.
Most responders (88.6%) considered static structural 
insult (such as hypoxic-ischemic encephalopathy, and hy-
poglycemic brain injury) as the commonest cause of WS 
in their practice. Around 30% responders from Pakistan 
had observed genetic causes of WS more commonly as 
compared with structural insult. For WS with unknown 
etiology, most responders would proceed with either meta-
bolic workup (first choice: 64/123; second choice: 44/123) 
or pyridoxine trial (first choice: 57/123; second choice: 
3/123) or vice versa. Some responders would straightaway Q
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go ahead with genetic testing—chromosomal microar-
ray (6/123), epileptic encephalopathy panel (8/123), and 
exome sequencing (7/123).
Hormonal therapy (ACTH or oral steroids) was the first-
line treatment used by most responders (97/123; 78.9%). In 
India, 38/76 (50%) use ACTH, 27/76 (35.5%) responders 
use oral steroids, 6/76 (8%) use a combination therapy (hor-
monal + vigabatrin), and 5/76 (7%) use valproate as the first 
drug for WS (Figure  1B). In Pakistan, the responders use 
oral steroids (10/22; 45.5%), vigabatrin (7/22; 31.8%%), and 
valproate (4/22; 18.2%) as the first-line drug. ACTH as the 
first-line therapy was chosen minimally (1/22). In Myanmar, 
Sri Lanka, and Nepal, oral steroids (17/18) were the preferred 
for first- line use. In Bangladesh, ACTH was preferred (2/2) 
while in Bhutan, oral steroids (2/5) and vigabatrin (3/5) were 
equally chosen.
More than 75% of responders from Pakistan, India, and 
Bangladesh used ACTH in their practice. However, it was not 
at all used by responders from Myanmar, Nepal, and Bhutan. 
The most commonly used preparation of ACTH was Acton 
Prolongatum (most responders for this question were from 
India–44/56) (Table 2). The most commonly used regimen 
was maximal-dose-at-initiation followed by tapering in India, 
Sri Lanka, and Bangladesh while in Pakistan, most respond-
ers followed a gradually escalating regimen with once-daily 
administration. For maximal-dose-at-initiation regimen, 
the initial dose ranged from 60-75  IU/day of ACTH. In 
Sri Lanka, responders followed an alternate day regime of 
ACTH. ACTH was mostly used in combination with other 
antiepileptic drugs (68/81).
The maximum dose of oral prednisolone ranged from 
2  mg/kg/d to 8  mg/kg/d (Table  2). Most responders from 
India used 3-4  mg/kg/d followed by 2  mg/kg/d. Most re-
sponders from Pakistan, Bhutan, and Bangladesh used 2 mg/
kg/d while those from Sri Lanka, Myanmar, and Nepal used 
a higher dose of 5-8 mg/kg/d or 40-60 mg/d. The duration 
for which hormonal therapy was administered ranged from 4 
to 12 weeks (67/91; 73.6%). Diverse regimes for blood pres-
sure monitoring ranging from daily to weekly were followed 
throughout India while in Pakistan, most advised weekly 
monitoring. Weekly monitoring for blood sugar was advised 
by most responders. Around 48% responders use prophylac-
tic antiepileptic drug after attaining remission with hormonal 
therapy (all from India, Pakistan, and Bangladesh). Most 
responders (70/92; 76.1%) treated early relapse (within one 
year) with repeat ACTH/ oral steroid therapy.
Vigabatrin was used by most responders in all the sur-
veyed nations except Myanmar and Nepal. Rate of escala-
tion of vigabatrin ranged from 25 mg/kg/3 days to 25 mg/
kg/wk (Table 3). The maximum duration for which vigaba-
trin was used ≤9 months (76/99, 76.8%). However, around 
25% responders (23/99) used vigabatrin for >9  months 
duration. Around one-third of responders do not monitor Q
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for ophthalmological problems such as visual field defect 
while on vigabatrin therapy while the rest routinely ad-
vised fundus examination, electroretinogram (ERG), or vi-
sually evoked potentials (VEP) for children on vigabatrin 
therapy.
Most responders considered a cessation of spasms for 
either four weeks (48.6%) or two weeks (41.5%) as a com-
plete response. Most responders advised EEG for evaluat-
ing the resolution of hypsarhythmia (104/123; 84.6%). Most 
responders would proceed with a second-line drug in cases 
with failure of clinical response in 14 days (73/121; 60.3%). 
Around 50% of responders (62/123) had a standard operating 
protocol for the management of WS at their center. More than 
95% of responders felt a need for more awareness regarding 
WS (Table 1).
3.2 | Results of systematic review and  
meta-analysis
Of 1012 studies screened, 18 studies fulfilled the eligibil-
ity criteria and were included for the meta-analysis (Figure 
S1).7,15–31 These studies were from three countries (India, 
Pakistan, and Sri Lanka), and there was no published study 
fulfilling eligibility criteria from Bangladesh, Bhutan, Nepal, 
and Myanmar. There was substantial heterogeneity among 
the studies for most variables—gender, LTTT, and struc-
tural etiology. However, the heterogeneity was low for the 
interventional studies testing the effectiveness of hormonal 
therapy (ACTH or hormonal therapy).
The pooled estimates for proportion of male gender, 
structural etiology, and acquired structural insult revealed 
preponderance of these variables [male gender: 68% (confi-
dence interval [CI] 64%-73%), structural etiology: 80% (CI 
73%-86%), acquired structural insult: 69% (CI: 61%-76%)] 
in the included studies (Figure 2A,B,C). For male gender, the 
pooled estimates varied among different countries from 58% 
in Sri Lanka to 72% in India.15–23,29 The pooled estimate for 
LTTT was 2.4 months (CI: 2.1-2.6 months) while for India, 
it was nearly two times [4.4  months (CI: 4-4.8  months)] 
(Figure 2D).17,18,20–22
For the effectiveness of hormonal therapy, limited num-
ber of interventional trials was available.7,19,23,29,31 These 
studies were from India and Sri Lanka. These studies used 
different dose regimes for ACTH and oral steroids, although 
the preparations were same, that is, Acton Prolongatum and 
prednisolone. The pooled estimates for electroclinical re-
sponse at day 14 and persistent cessation of spasms at day 
42 of ACTH therapy were 27% (CI: 14%-42%) and 18% (CI: 
9%-28%) while those for oral steroid were 33% (CI: 24%-
42%) and 28% (CI: 21%-37%), respectively (Figure 3A-D). 
For ACTH, the diamond was significantly skewed toward the 
Sri Lankan study (with a lower response rate, larger sample 
size, and hence weight).29 However, ACTH was used every 
other day in this study, and the dose was nearly half of that 
used in Indian studies.7,31
4 |  DISCUSSION
The current study brings forth management practices for WS 
in seven South Asian countries. A response rate of 56% was 
observed for the survey. This was much higher as compared 
with a survey of Child Neurology Society members (USA; 
18%) while this was low as compared with a survey in Japan 
(75%), probably due to wider regions covered.12,13 It was ob-
served that there is a wide diversity in the practices, and each 
country has its own challenges.
Most responders observed a male preponderance for WS. 
This concurs with the results of meta-analysis with a pooled 
male to female ratio of 2.1:1. However, the predilection for 
male gender varied among the countries in the meta-analysis 
with a pooled male to female ratio of 2.6:1 for India, 1.8:1 
for Pakistan, and 1.4:1 for Sri Lanka (Figure  2A).15–27,29 
Although slight male preponderance has also been reported 
globally (male: female- 1.5:1), the figures for South Asia (es-
pecially India) are definitely higher.2,11 This disparity may 
be explicated by the higher risk of perinatal complications 
such as intrauterine growth restriction, hypoxic-ischemic en-
cephalopathy (HIE), and hypoglycemia in male infants.11,32 
Another reason may be a higher proportion of males in the 
referred population.2
Most responders observed a longer LTTT (4-12  weeks) 
and the predominance of structural etiology. Interestingly, 
some responders from Pakistan observe genetic causes more 
commonly, probably due to higher consanguinity. These re-
sponses are in accord with the results of meta-analysis with 
a pooled mean LTTT of 2.4  months and a static structural 
insult to the tune of 80%.15–26,29,30 The longer LTTT estimate 
(4.4 months) and a higher preponderance of static structural 
insult (82%) and acquired structural insult (71%) in India are 
bothersome. The LTTT is relatively short in Western coun-
tries (<4 weeks) and is known to be the most important prog-
nostic factor in WS.5 Both these factors—a longer LTTT and 
a high proportion of static structural insult—may adversely 
affect the developmental outcomes for WS in South Asia. 
Acquired brain insult secondary to HIE, hypoglycemic brain 
injury, etc is fairly common in developing countries and is a 
common cause of WS.15–26,29,30 Despite the growing focus on 
perinatal and neonatal health, substantial mortality and mor-
bidity persists and a significant proportion of this is caused 
by preventable causes such as birth asphyxia and neonatal 
hypoglycemia. Thus, there is a growing need to prioritize the 
resources and research strategies at avoiding the preventable 
causes and reducing the diagnostic lag and thereby LTTT.
Lack of event recognition as seizure by parents was con-
sidered as the most common cause of treatment lag followed 
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by misdiagnosis by the initial attending physician. This high-
lights the poor awareness not only among the parents but also 
among the practitioners.14,18,20 Hence, there is an unmet need 
for creating awareness regarding WS. Home video recordings 
or video recordings by pediatricians may be helpful in early 
diagnosis and reducing LTTT. Also, the scarcity of pediatric 
EEG facilities in Bhutan and Nepal is worrisome. Although 
there is provision for free diagnosis and management in 
Bhutan, this cannot recompense the lack of infrastructure for 
diagnosis.
Akin to the rest of the world, hormonal therapy remains 
the mainstay of treatment. However, there is an inclination 
toward oral steroids in comparison with ACTH. This might 
be attributed to several reasons. These include nonavail-
ability of ACTH in Myanmar, Nepal, and Bhutan, cost of 
ACTH therapy, expenses being borne by patient families in 
most South Asian countries (instead of state as in the west-
ern countries), painful and cumbersome frequent injections 
of ACTH, mounting evidence for efficacy of oral steroids 
from South Asia, etc.24,29,30 This is also apparent in the me-
ta-analysis where the electroclinical response rates on day 14 
and persistent cessation of spasms on day 42 of ACTH and 
prednisolone therapy favor oral prednisolone. These response 
rates are much lower than those seen in Western countries. 
The possible reasons for this discrepancy include the prepon-
derance of structural etiology and a longer LTTT. Also, the 
F I G U R E  2  Forest plots for pooled estimates for gender, etiology, and diagnostic or treatment lag in children with West syndrome. 
Forest plots showing the South Asian and country-wise pooled estimates for the proportion of male gender (A), structural etiology (including 
intrauterine infections, malformations, and neurocutaneous syndromes) (B), acquired structural insult (including intrauterine infections; excluding 
malformations) (C), and lead time to diagnosis or treatment (in months; D) in children with West syndrome
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results of meta-analysis are predominantly based on the larg-
est trial from South Asia by Wanigasinghe et al which used 
an alternate-day regime for ACTH as compared with other 
Indian studies which reported response rates nearly two times 
of those reported in the Sri Lankan study.29
Different forms of ACTH are used in WS. These include nat-
ural ACTH (short-acting form derived from bovine or porcine 
source; used in the USA) and synthetic ACTH (such as tetraco-
sactide used in Europe and Asia; Acton prolongatum in Asia, 
etc).33 Natural ACTH (derived from animal sources) consists of 
39 amino acids with corticotrophic activity in initial 20 amino 
acids at N-terminal. The antigenic activity lies in the C-terminal 
portion (22-39 amino acids) of the molecule. Synthetic ACTH 
may contain all 39 amino acid residues (Acton Prolongatum-
porcine sequence) or lesser amino acids with biological activ-
ity (tetracosactide, cosyntropin, synacthen, etc containing 24 
amino acids). Also, these are usually constituted in depot form 
(Synacthen) or in combination with carboxymethyl cellulose 
(Acton Prolongatum) to allow for a longer duration of action.
The most commonly used preparation for ACTH in 
the seven surveyed countries was Acton prolongatum (a 
synthetic ACTH with porcine sequence). Natural ACTH 
is not available. Although there are no head-to-head clin-
ical trials comparing natural and synthetic ACTH, Acton 
Prolongatum is a cheaper (as compared with natural ACTH 
or Synacthen). The most commonly followed regime was 
maximal-dose-at-initiation (60-75  IU or 150  IU/m2). The 
rate of administration ranged from once daily in most coun-
tries to alternate day in Sri Lanka. Alternate-day tetracos-
actide administration has also been in practice in the UK, 
considering higher side effects with daily administration.34 
However, there are no head-to-head trials comparing daily 
with alternate-day administration and gradually escalating 
regime with maximal-dose-at-initiation regime. For oral 
steroids, United Kingdom Infantile Spasms Study (UKISS) 
regime is followed in Sri Lanka, Myanmar, and Nepal 
while a dose of 2-4  mg/kg/d is used in India, Pakistan, 
Bangladesh, and Bhutan.
F I G U R E  3  Forest plot showing the pooled estimates for response to hormonal therapy [adrenocorticotropic hormone (ACTH) and oral 
steroids] in children with West syndrome in South Asia. Forest plot showing the pooled estimates for electroclinical response at day 14 and 
persistent cessation of spasms at day 42 (among patients with freedom of spasms/ electroclinical response at day 14) of ACTH (A and B) and oral 
steroids (C and D) in South Asian children with West syndrome
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Vigabatrin was used by most responders in all the sur-
veyed nations except Myanmar and Nepal. However, there 
are issues with licensing and availability of the drug in most 
of the surveyed countries. The drug available is usually im-
ported, thereby adding to the cost of therapy. It is vexing that 
neither ACTH nor vigabatrin are licensed and available in 
Nepal and Myanmar while ACTH is not licensed and avail-
able in Bhutan. Vigabatrin is neither licensed and nor readily 
available in India. Around 20% of responders used vigabatrin 
for >9 months, which is known to predispose to visual field 
defects.
Standardized management protocols are known to be 
associated with better outcomes in WS.35 Hence, there is a 
need for the development of a standardized protocol for the 
management of WS at each center. Besides this, there is a 
need for consensus guidelines for South Asian subcontinent, 
considering the unique problems faced by these countries. 
Many of the problems which are common to these countries 
such as longer LTTT and structural etiology may be targeted 
as a group. However, despite several commonalities, estab-
lishing a unified protocol for management in these countries 
may be difficult considering the lack of proper facilities for 
investigations like EEG in some countries, availability issues 
with ACTH and vigabatrin in most of these countries, and 
probably different response rate of different populations to 
oral steroids and ACTH.
The current study is a singular study from South Asia on 
the management practices for WS, highlighting various chal-
lenges and providing a meta-analysis of available literature. 
Also, this study underscores the remediable problems such as 
difficult access to pediatric EEG, availability and licensing 
issues for drugs used in WS in many South Asian countries. 
Solutions to these may improve the outcomes of children 
with WS in South Asia.
This study was limited to a survey of the professionals in-
terested in the field. Besides, only two pediatric neurologists 
could be contacted in Bangladesh, and the response rate to 
the survey was around 50% in India (despite a high number) 
and Bhutan. Hence, this study may not be the most accurate 
depiction of the practices in these countries. But the concur-
rence between the results of survey and the meta-analysis 
suggests exactitude of the survey results.
5 |  CONCLUSION
This survey brings to light the practices and challenges in the 
management of WS in South Asia. The important practices 
comprise a preference of longer acting synthetic ACTH in 
India and Bangladesh, a preference for oral steroids/vigaba-
trin over ACTH in Sri Lanka, Nepal, and Bhutan, and wide 
variations in treatment regimens for ACTH, oral steroids, 
and vigabatrin across the region. The challenges include a 
longer LTTT, a preponderance of structural etiology, diffi-
cult access to pediatric EEG, and nonavailability of ACTH 
and vigabatrin in some countries. With teeming numbers of 
children with WS in these countries, pediatric neurologists 
should take these challenges as an opportunity for liaison 
for advocacy, develop a standardized management protocol, 
and conduct research to develop affordable and sustainable 
healthcare solutions to improve the long-term outcome in 
WS.
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